Earlier this month, the U.S. Commerce Department initiated a national security investigation into medical device imports, including those produced by major manufacturers such as ResMed, raising the possibility of tariffs and regulatory changes for the industry.

This move has introduced fresh uncertainty around supply chains and costs, particularly for companies with significant U.S. market exposure and global manufacturing operations.

We'll explore how the U.S. investigation into imported medical devices could reshape ResMed's outlook amid evolving regulatory risks.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

ResMed's investment story centers around capturing long-term growth from rising sleep health awareness, expanding home-based care, and ongoing innovation in respiratory therapies. The recent U.S. Commerce Department investigation into medical device imports does introduce fresh regulatory uncertainty, but its direct near-term impact on ResMed's primary catalysts, such as device adoption and digital health expansion, appears limited so far. That said, it does underscore novel risks around tariffs and compliance costs for companies with global supply chains.

Among recent announcements, ResMed's launch of the NightOwl™ home sleep apnea test stands out as a catalyst directly supporting its strategy of expanding the patient funnel. This aligns with broader themes driving demand for at-home diagnostics and sleep therapy, which underpin forecasts for ongoing revenue and margin growth. However, rising regulatory scrutiny on imported medical equipment creates a backdrop where operational and compliance risk is...

Read the full narrative on ResMed (it's free!)

ResMed's narrative projects $6.4 billion revenue and $1.9 billion earnings by 2028. This requires 7.8% yearly revenue growth and a $0.5 billion earnings increase from $1.4 billion today.

Uncover how ResMed's forecasts yield a $291.86 fair value, a 8% upside to its current price.

Eight members of the Simply Wall St Community estimate ResMed's fair value between US$179.72 and US$291.86 per share. With new regulatory threats on the horizon, your outlook on evolving supply chain and tariff risks could make a real difference to your expectations for the company's performance.

Explore 8 other fair value estimates on ResMed - why the stock might be worth 34% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your ResMed research is our analysis highlighting 3 key rewards that could impact your investment decision.

Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ResMed's overall financial health at a glance.

Our top stock finds are flying under the radar-for now. Get in early:

We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Outshine the giants: these 25 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include RMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com